ExoCoBio Competitors and Similar CompaniesClear all
ExoCoBio's competitors and similar companies include Gamida Cell, Innate Pharma, OncoDNA and A2 Biotherapeutics.
 ExoCoBio ExoCoBio is a company developing therapeutics as well as cosmetic products based on stem cell-derived exosomes. |  Gamida Cell Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases. |  Innate Pharma Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. |  OncoDNA OncoDNA is a cancer theranostic company which uses a combination of the relevant molecular technologies to support oncologists in their treatment decisions for patients. |  A2 Biotherapeutics A2 Biotherapeutics is a biotechnology company that develops cell therapies for cancer patients. | |
Founding Date | Founding Date 2017 | Founding Date 1998 | Founding Date 1999 | Founding Date 2012 | Founding Date 2018 |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations KR HQ | Locations Boston, US HQ Jerusalem, IL | Locations Marseille, FR HQ Rockville, US | Locations Charleroi, BE HQ | Locations Agoura Hills, US HQ |
Employees | Employees 25 | Employees 143175% increase | Employees 181 | Employees 502% increase | Employees 1255% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 4.3 m | Valuation ($) 148.6 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $1.8m (FY, 2023) | Revenue (est.) €2.8m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods $1.5m (FY, 2023) | Cost of goods €266k (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $330k (FY, 2023) | Gross profit €8.7m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income N/A | Net income ($63m) (FY, 2023) | Net income (€49.2m) (FY, 2025) | Net income N/A | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round $ 9.3m (over 5 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 20.6m (over 6 years ago) | Latest funding round $ 71.5m (over 5 years ago) |
Total funding raised | Total funding raised $ 47m | Total funding raised $ 128.3m | Total funding raised $ 94.1m | Total funding raised $ 29.8m | Total funding raised $ 128.5m |
For sources of this data, please see the company profile
View Company Profiles
Gamida Cell
HQ
Boston, US
Employees
143
Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases.
View companyInnate Pharma
HQ
Marseille, FR
Employees
181
Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
View companyOncoDNA
HQ
Charleroi, BE
Employees
50↑ 2% increase
OncoDNA is a cancer theranostic company which uses a combination of the relevant molecular technologies to support oncologists in their treatment decisions for patients.
View companyA2 Biotherapeutics
HQ
Agoura Hills, US
Employees
125↓ 5% decrease
A2 Biotherapeutics is a biotechnology company that develops cell therapies for cancer patients.
View company